Abstract:Background Expression of kappa gene is under the control of distinct cis-regulatory elements, including the kappa intron enhancer (iE κ ) and the kappa 3' enhancer (3'E κ ). The active enhancers and expression of immunoglobulin is generally considered to be restricted to B lymphocytes. However, accumulating evidence indicated that epithelial cancer cells, including nasopharyngeal carcinoma (NPC) cell lines, express immunoglobulins. The mechanisms underlying the expression of Igs in nonlymphoid cells remain unknown. On the basis of our previous finding that expression of kappa light chain in NPC cells can be upregulated by EBV-encoded latent membrane protein 1(LMP1) through the activation of NF-κB and AP-1 signaling pathways, we thus use NPC cells as model to further explore the molecular mechanisms of nonlymphoid cells expressing Ig kappa. Results In this study, luciferase reporter plasmid containing human wild-type iE κ , and its derivative plasmids containing mutant binding sites for transcription factor NF-κB or AP-1 were constructed. Luciferase reporter assays demonstrate iE κ is active in Igκ-expressing NPC cells and LMP1 expression can upregulate the activity of iE κ in NPC cells. Mutation of the NF-κB or AP-1 site within and downstream the iE κ , inhibition of the NF-κB and AP-1 pathways by their respective chemical inhibitor Bay11-7082 and SP600125 as well as stable or transient expression of dominant-negative mutant of IκBα (DNMIκBα) or of c-Jun (TAM67) indicate that both sites are functional and LMP1-enhanced iE κ activity is partly regulated by these two sites. Gel shift assays show that LMP1 promotes NF-κB subunits p52 and p65 as well as AP-1 family members c-Jun and c-Fos binding to the κNF-κB and the κAP-1 motifs in vitro , respectively. Both chemical inhibitors and dominant negative mutants targeting for NF-κB and AP-1 pathways can attenuate the LMP1-enhanced bindings. Co-IP assays using nuclear extracts from HNE2-LMP1 cells reveal that p52 and p65, c-Jun and c-Fos proteins interact with each other at endogenous levels. ChIP assays further demonstrate p52 and p65 binding to the κB motif as well as c-Jun and c-Fos binding to the AP-1 motif of Ig kappa gene in vivo . Conclusion These results suggest that human iE κ is active in Igκ-expressing NPC cells and LMP1-stimulated NF-κB and AP-1 activation results in an augmenting activation of the iE κ . LMP1 promotes the interactions of heterodimeric NF-κB (p52/p65) and heterodimeric AP-1 (c-Jun/c-Fos) transcription factors with the human iE κ enhancer region are important for the upregulation of kappa light chain in LMP1-positive nasopharyngeal carcinoma cells.

LMP1 Activates NF-kappa B Via Degradation of I Kappa B Alpha in Nasopharyngeal Carcinoma Cells.

LMP1 Activates NF-κB Via Degradation of IκBα in Nasopharyngeal Carcinoma Cells

The Epstein-Barr Virus Encoded Latent Membrane Protein 1 Promotes Nuclear Factor-kappa B Activity in a Nasopharyngeal Carcinoma Cell Line

Epstein-Barr Virus Encoded Latent Membrane Protein 1 Increases Expression of Immunoglobulin Kappa Light Chain Through NFkappaB in a Nasopharyngeal Carcinoma Cell Line.

Epstein-barr Virus-Encoded Latent Membrane Protein 1 Activates NF-κ B Via a Mechanism Involving TRAF2 in Nasopharyngeal Carcinoma

Epstein-Barr Virus Latent Membrane Protein 1 Induces Telomerase Activity of Nasopharyngeal Epithelial Cells Through NFκB

Epstein-Barr Virus Latent Membrane Protein1(LMP1) Activated Ets-1 Expression Mediated by ERK in Nasopharyngeal Cell Line

Epstein–Barr virus encoded latent membrane protein 1 modulates nuclear translocation of telomerase reverse transcriptase protein by activating nuclear factor-κB p65 in human nasopharyngeal carcinoma cells

Epstein-Barr virus LMP1 triggers the expression of inhibitor of apoptosis protein survivin via NF kappa B and AP-1 signaling pathways in nasopharyngeal carcinoma

[EB Virus Encoded Latent Membrane Protein 1 Modulates the Phosphorylation of Epidermal Growth Factor Receptor in Nasopharyngeal Carcinoma Cell Line].

Cells in G 2 /M Phase Increased in Human Nasopharyngeal Carcinoma Cell Line by EBV-LMP1 Through Activation of NF- Κ B and AP-1

Epstein-Barr virus latent membrane protein 1 modulates epidermal growth factor receptor promoter activity in a nuclear factor kappa B-dependent manner.

Epstein-Barr Virus LMP-1 Activated AP-1 Mediated by JNK in Nasopharyngeal Cell Line

RETRACTED: Nuclear Factor Kappa B (nfκb) Dependent Modulation of Epstein–Barr Virus Latent Membrane Protein 1 (LMP1) in Epidermal Growth Factor Receptor (EGFR) Promoter Activity

Nuclear Accumulation of Epidermal Growth Factor Receptor and Acceleration of G1/S Stage by Epstein–Barr-encoded Oncoprotein Latent Membrane Protein 1

[Matrix Metalloproteinase 9 Expression is Induced by Epstein-Barr Virus LMP1 Via NF-kappa B or AP-1 Signaling Pathway in Nasopharyngeal Carcinoma Cells].

Interaction of Tumor Necrosis Factor Receptor-Associated Factors with the Latent Membrane Protein 1 is Essential for Activation of Nf-Kappa B

Role of Epstein-Barr Virus Encoded Latent Membrane Protein 1 in the Carcinogenesis of Nasopharyngeal Carcinoma.

LMP1-augmented kappa intron enhancer activity contributes to upregulation expression of Ig kappa light chain via NF-kappaB and AP-1 pathways in nasopharyngeal carcinoma cells

Upregulated Expression of Kappa Light Chain by Epstein–Barr Virus Encoded Latent Membrane Protein 1 in Nasopharyngeal Carcinoma Cells Via NF-κB and AP-1 Pathways

Epstein-Barr Virus Lmp1 Initiates Cell Proliferation and Apoptosis Inhibition Via Regulating Expression of Survivin in Nasopharyngeal Carcinoma